Skip to main content

Advertisement

SpringerLink
Log in

Probiotiques et maladies inflammatoires cryptogénétiques de l’intestin

Probiotics and inflammatory bowel disease

  • Formation Continue
  • Phytothérapie Clinique
  • Published:
Phytothérapie

Résumé

Les probiotiques font l’objet de recherches actives dans les maladies inflammatoires chroniques de l’intestin. Un niveau de preuve satisfaisant d’efficacité ne peut être obtenu qu’avec des essais randomisés contrôlés. L’Escherichia coli Nissle 1917 est efficace dans la prévention de rechute de la rectocolite hémorragique (RCH). Le produit VSL#3 est efficace pour diminuer le risque de pochite. Les études dans la maladie de Crohn (MC) sont à ce jour soit négatives, soit insuffisantes. Les nombreux produits commercialisés sans étude ne doivent pas être employés, mais dénoncés.

Abstract

Probiotics are actively investigated in inflammatory bowel disease. Evidence of efficacy can only be obtained by randomized controlled trials. Escherichia coli Nissle 1917 is effective to prevent recurrence of ulcerative colitis. VSL#3 reduces the risk of pouchitis. All studies performed until now in Crohn’s disease have been negative or insufficient. Many commercial products without studies and with misleading claims should be blamed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Références

  1. Bibiloni R, Fedorak RN, Tannock GW, et al. (2005) VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol 100: 1539–1546

    Article  PubMed  Google Scholar 

  2. Bousvaros A, Guandalini S, Baldassano RN, et al. (2005) A randomised, double blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn’s disease. Inflamm Bowel Dis 11: 833–839

    Article  PubMed  Google Scholar 

  3. Chermesh I, Tamir A, Reshef R, et al. (2007) Failure of Synbiotic 2000 to prevent postoperative recurrence of Crohn’s Disease. Dig Dis Sci 52: 385–389

    Article  PubMed  Google Scholar 

  4. Desreumaux P, Dewit O, Belaiche J, et al. (2009) Prevention of Crohn’s disease postsurgical recurrence with Lactobacilluscasei DN-114001 strain: an European multicentric double blind clinical trial. Gut 58(Suppl II): A616

    Google Scholar 

  5. Doherty G, Bennett G, Patil S, et al. (2009) Interventions for prevention of postoperative recurrence of Crohn’s disease. Cochrane Database Syst Rev 4: CD006873

    PubMed  Google Scholar 

  6. FAO/WHO (2001) Health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. www.who.int/foodsafety/publications/fs_management/en/probiotics.pdf

  7. Gionchetti P, Rizzello F, Venturi A, et al. (2000) Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double blind, placebo-controlled trial. Gastroenterology 119: 305–309

    Article  PubMed  CAS  Google Scholar 

  8. Gionchetti P, Rizzello F, Helwig U, et al. (2003) Prophylaxis of pouchitis onset with probiotic therapy: a double blind, placebo-controlled trial. Gastroenterology 124: 1202–1209

    Article  PubMed  Google Scholar 

  9. Guslandi M, Mezzi G, Sorghi M, Testoni PA (2000) Saccharomycesboulardii in maintenance treatment of Crohn’s disease. Dig Dis Sci 45: 1462–1464

    Article  PubMed  CAS  Google Scholar 

  10. Kato K, Mizuno S, Umesaki Y, et al. (2004) Randomised placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Aliment Pharmacol Ther 20: 1133–1141

    Article  PubMed  CAS  Google Scholar 

  11. Kruis W, Schutz E, Fric P, et al. (1997) Double blind comparison of an oral Escherichiacoli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 11: 853–858

    Article  PubMed  CAS  Google Scholar 

  12. Kruis W, Fric P, Pokrotnieks J, et al. (2004) Maintaining remission of ulcerative colitis with the probiotic Escherichiacoli Nissle 1917 is as effective as with standard mesalazine. Gut 53: 1617–1623

    Article  PubMed  CAS  Google Scholar 

  13. Madsen K, Backer JL, Leddin D, et al. (2008) A randomised controlled trial of VSL#3 for the prevention of endoscopic recurrence following surgery for Crohn’s disease. Gastroenterology 134(Suppl): A361

    Google Scholar 

  14. Marteau P, Shanahan F (2003) Basic aspects and pharmacology of probiotics: an overview of pharmacokinetics, mechanisms of action and side-effects. Best Pract Res Clin Gastroenterol 17: 725–740

    Article  PubMed  CAS  Google Scholar 

  15. Marteau P, Lemann M, Seksik P, et al. (2006) Ineffectiveness of Lactobacillusjohnsonii LA1 for prophylaxis of postoperative recurrence in Crohn’s disease: a randomised, double blind, placebo controlled GETAID trial. Gut 55: 842–847

    Article  PubMed  CAS  Google Scholar 

  16. Melgar S, Shanahan F (2010) Inflammatory bowel disease — from mechanisms to treatment strategies. Autoimmunity 43: 463–477

    Article  PubMed  Google Scholar 

  17. Mimura T, Rizzello F, Helwig U, et al. (2004) Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 53: 108–114

    Article  PubMed  CAS  Google Scholar 

  18. Prantera C, Scribano ML, Falasco G, et al. (2002) Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn’s disease: a randomised controlled trial with Lactobacillus GG. Gut 51: 405–409

    Article  PubMed  CAS  Google Scholar 

  19. Pronio A, Montesani C, Butteroni C, et al. (2008) Probiotic administration in patients with ileal pouchanal anastomosis for ulcerative colitis is associated with expansion of mucosal regulatory cells. Inflamm Bowel Dis 14: 662–668

    Article  PubMed  Google Scholar 

  20. Rembacken BJ, Snelling AM, Hawkey PM, et al. (1999) Non-pathogenic Escherichiacoli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 354: 635–639

    Article  PubMed  CAS  Google Scholar 

  21. Shen B, Brzezinski A, Fazio VW, et al. (2005) Maintenance therapy with a probiotic in antibiotic-dependent pouchitis: experience in clinical practice. Aliment Pharmacol Ther 22: 721–728

    Article  PubMed  CAS  Google Scholar 

  22. Sokol H, Pigneur B, Watterlot L, et al. (2008) Faecalibacteriumprausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A 105: 16731–16736

    Article  PubMed  CAS  Google Scholar 

  23. Sood A, Midha V, Makharia GK, et al. (2009) The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin Gastroenterol Hepatol 7: 1202–1209

    Article  PubMed  Google Scholar 

  24. Travis SP, Stange EF, Lémann M, et al. for the European Crohn’s and Colitis Organisation (ECCO) (2008) European evidence-based Consensus on the management of ulcerative colitis: Current management. J Crohns Colitis 2: 24–62

    Article  PubMed  Google Scholar 

  25. Tursi A, Brandimarte G, Giorgetti GM, et al. (2004) Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Med Sci Monit 10: PI126–PI131

    PubMed  CAS  Google Scholar 

  26. Tursi A, Brandimarte G, Papa A, et al. (2010) Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double blind, randomised, placebo-controlled study. Am J Gastroenterol 105: 2218–2227

    Article  PubMed  Google Scholar 

  27. Van Gossum A, Dewit O, Louis E, et al. (2007) Multicenter randomised-controlled clinical trial of probiotics (Lactobacillusjohnsonii, LA1) on early endoscopic recurrence of Crohn’s disease after ileocaecal resection. Inflamm Bowel Dis 13: 135–142

    Article  PubMed  Google Scholar 

  28. Zocco MA, dal Verme LZ, Cremonini F, et al. (2006) Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 23: 1567–1574

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Université Denis-Diderot, F-75013, Paris-VII, France

    P. Marteau

  2. Laboratoire de biologie EA 3199, CNAM, 2, rue Conté, F-75003, Paris, France

    P. Marteau

  3. Département médicochirurgical de pathologie digestive, hôpital Lariboisière, 2, rue Ambroise-Paré, F-75475, Paris cedex, France

    P. Marteau & M. Camus

Authors
  1. P. Marteau
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Camus
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P. Marteau.

About this article

Cite this article

Marteau, P., Camus, M. Probiotiques et maladies inflammatoires cryptogénétiques de l’intestin. Phytothérapie 9, 113–116 (2011). https://doi.org/10.1007/s10298-011-0614-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10298-011-0614-9

Mots clés

Keywords

Search

Navigation